Tempest Therapeutics, Inc. (TPST) Stock Analysis & Investment Frameworks

Tempest Therapeutics, Inc. (TPST) stock analysis on Invetso. Review Tempest Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Tempest Therapeutics, Inc. Company Overview

Tempest Therapeutics, Inc. Key Financial Metrics

About Tempest Therapeutics, Inc.

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

Tempest Therapeutics, Inc. Investment Frameworks

Invetso analyzes Tempest Therapeutics, Inc. (TPST) across the following frameworks:

Explore More TPST Research